Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions in ...

Teos' Belrestotug shows efficacy in trials, backed by a strong cash runway. Learn why ITOS stock might thrive with strategic ...

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...

Compugen Ltd (CGEN) showcases promising developments in oncology treatments while navigating a decrease in annual revenue and ...

The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell types has made it a ...

Reports Q4 revenue $1.5M, consensus $17.47M. Expects current cash will be sufficient to fund its operating plans into 2027. “I believe Compugen ...

Arcus Biosciences, Inc.’s RCUS share price has surged by 10.22%, which has investors questioning if this is right time to ...

Compugen (NASDAQ:CGEN – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of $0.07 ...

Although immune checkpoint inhibitors have shown noticeable clinical benefits, tumor evasion of single-agent immunotherapy occurs in some patients due to the compensatory role of alternative immune ...